相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials
Luciano J. Costa et al.
LEUKEMIA (2021)
Standardization of flow cytometric minimal residual disease assessment in international clinical trials. A feasibility study from the European Myeloma Network
Davine Hofste op Bruinink et al.
HAEMATOLOGICA (2021)
CAR T-cell therapy in multiple myeloma: more room for improvement
Phaik Ju Teoh et al.
BLOOD CANCER JOURNAL (2021)
VS38 Identifies Myeloma Cells With Dim CD38 Expression and Plasma Cells Following Daratumumab Therapy, Which Interferes With CD38 Detection for 4 to 6 Months
Elizabeth L. Courville et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2020)
Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis
Herve Avet-Loiseau et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2020)
Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma
Bruno Paiva et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Methodological considerations for the high sensitivity detection of multiple myeloma measurable residual disease
Kah Teong Soh et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2020)
Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma
Stefania Oliva et al.
FRONTIERS IN ONCOLOGY (2020)
Validated single-tube multiparameter flow cytometry approach for the assessment of minimal residual disease in multiple myeloma
Sandra Maria Dold et al.
HAEMATOLOGICA (2020)
Minimal Residual Disease in Multiple Myeloma: Current Landscape and Future Applications With Immunotherapeutic Approaches
Ioannis V. Kostopoulos et al.
FRONTIERS IN ONCOLOGY (2020)
Minimal Residual Disease in Multiple Myeloma: State of the Art and Applications in Clinical Practice
Alessandro Gozzetti et al.
JOURNAL OF PERSONALIZED MEDICINE (2020)
A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma
Nikhil C. Munshi et al.
BLOOD ADVANCES (2020)
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
Alejandro Medina et al.
BLOOD CANCER JOURNAL (2020)
Standardization of 8-color flow cytometry across different flow cytometer instruments: A feasibility study in clinical laboratories in Switzerland
Hana Glier et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2019)
Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy
Luzalba Sanoja-Flores et al.
BLOOD (2019)
Comments on EuroFlow standard operating procedures for instrument setup and compensation for BD FACS Canto II, Navios and BD FACS Lyric instruments
Hana Glier et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2019)
Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma
Aurore Perrot et al.
BLOOD (2018)
A QA Program for MRD Testing Demonstrates That Systematic Education Can Reduce Discordance Among Experienced Interpreters
Michael Keeney et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2018)
Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes
O. Landgren et al.
JOURNAL OF INTERNAL MEDICINE (2017)
Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma
J. Flores-Montero et al.
LEUKEMIA (2017)
Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma A Meta-analysis
Nikhil C. Munshi et al.
JAMA ONCOLOGY (2017)
MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods
Mikhail Roshal et al.
BLOOD ADVANCES (2017)
Consensus Guidelines on Plasma Cell Myeloma Minimal Residual Disease Analysis and Reporting
Maria Arroz et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2016)
Assessment of Minimal Residual Disease in Myeloma and the Need for a Consensus Approach
Andy C. Rawstron et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2016)
Consensus Guidelines for Myeloma Minimal Residual Disease Sample Staining and Data Acquisition
Maryalice Stetler-Stevenson et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2016)
Immunophenotype of Normal vs. Myeloma Plasma Cells: Toward Antibody Panel Specifications for MRD Detection in Multiple Myeloma
Juan Flores-Montero et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2016)
Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis
O. Landgren et al.
BONE MARROW TRANSPLANTATION (2016)
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar et al.
LANCET ONCOLOGY (2016)
Marked Variability in Reported Minimal Residual Disease Lower Level of Detection of 4 Hematolymphoid Neoplasms A Survey of Participants in the College of American Pathologists Flow Cytometry Proficiency Testing Program
Michael Keeney et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2015)
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Sagar Lonial et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
H. M. Lokhorst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential
T. Paino et al.
LEUKEMIA (2015)
Comparison of cross-platform flow cytometry minimal residual disease evaluation in multiple myeloma using a common antibody combination and analysis strategy
Stéphanie Mathis et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2014)
Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity
Aaron Flanders et al.
BLOOD (2013)
EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols
T. Kalina et al.
LEUKEMIA (2012)
Improved survival in multiple myeloma and the impact of novel therapies
Shaji K. Kumar et al.
BLOOD (2008)
Assessment of bone marrow plasma cell infiltrates in multiple myeloma: the added value of CD138 immunohistochemistry
Samer Z. Al-Quran et al.
HUMAN PATHOLOGY (2007)
分享论文
